



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

22 May 2019
EMA/CAT/287669/2019
Inspections, Human Medicines Pharmacovigilance and Committees Division

Committee for Advanced Therapies (CAT)

Agenda for the meeting on 22-24 May 2019

Chair: Martina Schübler-Lenz; Vice-Chair: Ilona Reischl

22 May 2019, 14:00 – 18:30, room 0-C

23 May 2019, 09:00 – 18:30, room 0-C

24 May 2019, 09:00 – 12:00, room 0-C

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



Table of contents

1.	Introduction	5
1.1.	Welcome and declarations of interest of members, alternates and experts	5
1.2.	Adoption of agenda	5
1.3.	Adoption of the minutes	5
1.4.	Technical information	5
2.	Evaluation of ATMPs	5
2.1.	Opinions	5
2.2.	Oral explanations	5
2.3.	Day 180 list of outstanding issues	5
2.4.	Day 120 list of questions	5
2.5.	Day 80 assessment reports.....	5
2.6.	Update on ongoing initial applications.....	5
2.7.	New applications	6
2.8.	Withdrawal of initial marking authorisation application	6
2.9.	Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004	6
2.10.	GMP and GCP inspections requests	6
2.11.	Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008.....	6
2.11.1.	Alofisel - darvadstrocel - Orphan - EMEA/H/C/004258/II/0006	6
2.11.2.	Spherox - spheroids of human autologous matrix-associated chondrocytes - EMEA/H/C/002736/II/0005/G	6
2.11.3.	YESCARTA - axicabtagene ciloleucel - Orphan - EMEA/H/C/004480/II/0007	7
2.11.4.	Zalmoxis - nalotimagene carmaleucel - Orphan - EMEA/H/C/002801/II/0016	7
2.12.	Other Post-Authorisation Activities	7
2.12.1.	Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/ANX/009.....	7
2.12.2.	Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090	7
2.12.3.	Zalmoxis - nalotimagene carmaleucel - Orphan - EMEA/H/C/002801/R/0015.....	7
3.	Certification of ATMPs	8
3.1.	Opinion.....	8
3.2.	Day 60 Evaluation Reports.....	8
3.3.	New Applications.....	8
4.	Scientific Recommendation on Classification of ATMPs	8
4.1.	New requests – Appointment of CAT Coordinator	8
4.1.1.	Modified Vaccinia Ankara-Bavarian Nordic- Brachyury (MVA-BN-Brachyury) and recombinant fowlpox virus (FPV-Brachyury) encoding the human brachyury gene and three human costimulatory molecules known as TRICOM (triad of costimulatory molecules): B7.1,	

	intercellular adhesion molecule-1 (ICAM-1), and leukocyte function-associated antigen-3 (LFA-3) – H0005394	8
4.1.2.	Autologous CD34 ⁺ cells – H0005399	8
4.1.3.	Uncapped, non-coding ribonucleic acid – H0005400	8
4.1.4.	Messenger ribonucleic acid (mRNA) coding for coiled-coil domain-containing protein 40 (CCDC40) protein – H0005395.....	9
4.1.5.	Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor – H0005396.....	9
4.2.	Day 30 ATMP scientific recommendation	9
4.2.1.	Human embryonic stem cell-derived Müller cells – H0005356.....	9
4.2.2.	Allogeneic neonatal human cardiac progenitor cells – H0005357	9
4.2.3.	Allogeneic human enucleated red cell therapy expressing <i>Anabaena variabilis</i> (Av) phenylalanine ammonia lyase (AvPAL) – H0005355	9
4.3.	Day 60 revised scientific recommendation (following list of questions)	9
4.4.	Finalisation of procedure	10
4.4.1.	Autologous adipose tissue/micronised adipose tissue - H0005338/0001	10
4.4.2.	Allogeneic haematopoietic stem and progenitor cells treated ex vivo with the protein transduction domain of the human immunodeficiency virus-1 (HIV-1) transactivation protein fused to MYC transcription factor - H0005340/0001	10
4.4.3.	Allogeneic haematopoietic stem and progenitor cells treated ex vivo with the protein transduction domain of the human immunodeficiency virus-1 (HIV-1) transactivation protein fused to MYC transcription factor - H0005341/0001	10
4.4.4.	Autologous dendritic cell, electroporated with messenger ribonucleic acid (mRNA) encoding tumour antigen Wilms tumour r (WT)-1 – H0005240.....	10
4.5.	Follow-up and guidance.....	10
5.	Scientific Advice	10
5.1.	New requests – appointment of CAT Rapporteurs.....	11
5.2.	CAT reports.....	11
5.3.	List of Issues	11
5.4.	Finalisation of SA procedures	11
6.	Pre-Authorisation Activities	11
6.1.	Paediatric investigation plans.....	11
6.2.	ITF briefing meetings in the field of ATMPs	11
6.3.	Priority Medicines (PRIME) – Eligibility requests	11
6.3.1.	Month 0 - Start of the procedure	11
6.3.2.	Month 1 – Discussion of eligibility	11
6.3.3.	Month 2 – Recommendation of eligibility.....	11
6.3.4.	Ongoing support	11

7.	Organisational, regulatory and methodological matters	11
7.1.	Mandate and organisation of the CAT	11
7.1.1.	Strategic Review & Learning meeting – joint CAT/Clinical trial facilitation group (CTFG), Bucharest, Romania, 13-14 June 2019	11
7.1.2.	Strategic Review & Learning meeting – joint CAT/COMP/PDCO, Helsinki, Finland, 20-21 November 2019	12
7.2.	Coordination with EMA Scientific Committees.....	12
7.2.1.	Committee for Medicinal Products for Human Use (CHMP)	12
7.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups.....	12
7.3.1.	Healthcare Professionals Working Party (HCPWP) and Patients and Consumers Working Party (PCWP) - Nomination of CAT representative(s)	12
7.4.	Cooperation within the EU regulatory network	12
7.4.1.	Notice to applicants	12
7.4.2.	European Commission - draft guidelines on good clinical practice for advanced therapy medicinal products	12
7.4.3.	European Commission's Research and Innovation (R&I) Framework Programme	12
7.5.	Cooperation with international regulators	13
7.5.1.	ATMP cluster teleconference with FDA, Health Canada and PMDA	13
7.5.2.	International pharmaceutical regulators programme (IPRP) – cell therapy and gene therapy working groups	13
7.5.3.	Revision of Annex 2 of Pharmaceutical Inspection Co-operation Scheme (PIC/S) Good Manufacture Practice Guide.....	13
7.6.	CAT work plan	13
7.7.	Planning and reporting	13
7.8.	Others	13
8.	Any other business	13
8.1.	BREXIT: extension of the period under 'Article 50'	13
9.	Explanatory notes	14

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CAT plenary session to be held 22-24 May 2019. See May 2019 CAT minutes (to be published post June 2019 CAT meeting).

1.2. Adoption of agenda

CAT agenda for 22-24 May 2019 meeting

1.3. Adoption of the minutes

CAT minutes for 15-17 April 2019 meeting

1.4. Technical information

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

No items

2.3. Day 180 list of outstanding issues

No items

2.4. Day 120 list of questions

No items

2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

No items

2.7. New applications

2.8. Withdrawal of initial marking authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Alofisel - darvadstrocel - Orphan - EMEA/H/C/004258/II/0006

Takeda Pharma A/S

Rapporteur: Lisbeth Barkholt, CHMP Coordinator: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: submission of an updated RMP (version 7) in order to propose the replacement of the existing observational PASS (listed as category 3 study: 'a study to evaluate the long term safety of Alofisel (darvadstrocel (Cx601)) in patients treated and retreated (i.e. repeated dosing and immunogenicity) and to assess the effectiveness of Alofisel (darvadstrocel) in patients treated and retreated (i.e. repeated dosing) in routine clinical practice (for treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn's disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy)' with two separate studies: 1) a long-term safety extension of the ADMIRE-CD II study; a phase 3 randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess efficacy and safety of darvadstrocel (Cx601), allogeneic expanded adipose-derived stem cells for complex perianal fistula(s) in Crohn's disease; and 2) a retreatment PASS. The European multi-database linkage study is added for the assessment of the potential risk of tumourgenicit. Opinion

Action: for adoption

2.11.2. Spherox - spheroids of human autologous matrix-associated chondrocytes - EMEA/H/C/002736/II/0005/G

CO.DON AG

Rapporteur: Lisbeth Barkholt

Scope: safety: update of the product information to reflect the study results of the 36-month follow up data for trial cod 16 HS 13 and the final study report with 60-month follow-up data for trial cod 16 HS 14. Study cod 16 HS 13 is a prospective, randomised, open label, multicentre Phase-III clinical trial to compare the efficacy and safety of the treatment with the autologous chondrocyte transplantation product co.don chondrosphere (ACT3D-CS) with microfracture in subjects with cartilage defects of the knee with a defect size between 1 and 4 cm². Study cod 16 HS 14 is a prospective, randomised, open label, multicentre Phase-II clinical trial to investigate the efficacy and safety of the treatment of large defects (4-10 cm²) with three different doses of the autologous chondrocyte transplantation product co.don

chondrosphere (ACT3D-CS) in subjects with cartilage defects of the knee. Request for supplementary information (RSI)

Action: for adoption

2.11.3. YESCARTA - axicabtagene ciloleucel - Orphan - EMEA/H/C/004480/II/0007

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus

Scope: quality Request for supplementary information (RSI)

Action: for adoption

2.11.4. Zalmoxis - nalotimagene carmaleucel - Orphan - EMEA/H/C/002801/II/0016

MolMed S.p.A

Rapporteur: Carla Herberts, Co-Rapporteur: Sol Ruiz, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: the MAH is proposing to terminate the study TK008 (specific obligation for the CMA) and replace it with study TK013. Request for supplementary information (RSI)

Action: for adoption

See also 2.12.3

2.12. Other Post-Authorisation Activities

2.12.1. Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/ANX/009

Novartis Europharm Limited

Rapporteur: Rune Kjekken

Scope: (from initial MAA) Study CCTLO19H2301: Post-authorisation efficacy study (PAES): In order to further characterise the long-term efficacy and safety of Kymriah in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), the applicant should submit the results of study CCTLO19H2301 - open-label, Phase III study of Kymriah versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. (Category 1). Request for supplementary information (RSI)

Action: for adoption

2.12.2. Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090

Novartis Europharm Limited

Rapporteur: Rune Kjekken; CHMP Coordinator: Bjorg Bolstad

Scope: quality

Action: for discussion

2.12.3. Zalmoxis - nalotimagene carmaleucel - Orphan - EMEA/H/C/002801/R/0015

MolMed S.p.A

Rapporteur: Carla Herberts, Co-Rapporteur: Sol Ruiz, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: annual renewal of marketing authorisation

Action: for adoption

See also 2.11.4.

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

4. Scientific Recommendation on Classification of ATMPs

4.1. New requests – Appointment of CAT Coordinator

4.1.1. Modified Vaccinia Ankara-Bavarian Nordic- Brachyury (MVA-BN-Brachyury) and recombinant fowlpox virus (FPV-Brachyury) encoding the human brachyury gene and three human costimulatory molecules known as TRICOM (triad of costimulatory molecules): B7.1, intercellular adhesion molecule-1 (ICAM-1), and leukocyte function-associated antigen-3 (LFA-3) – H0005394

Intended for the treatment of chordoma

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

4.1.2. Autologous CD34⁺ cells – H0005399

Intended for the treatment of no-option critical limb ischemia

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

4.1.3. Uncapped, non-coding ribonucleic acid – H0005400

Intended for the treatment of adenoid cystic carcinoma, squamous cell carcinoma of the head and neck, melanoma and squamous cell carcinoma of the skin

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

4.1.4. Messenger ribonucleic acid (mRNA) coding for coiled-coil domain-containing protein 40 (CCDC40) protein – H0005395

Intended for the treatment of primary ciliary dyskinesia (PCD) caused by biallelic mutation in the CCDC40 gene

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

4.1.5. Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor – H0005396

Intended for the treatment of various types of cancer

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

4.2. Day 30 ATMP scientific recommendation

4.2.1. Human embryonic stem cell-derived Müller cells – H0005356

Intended for the treatment of primary open angle glaucoma

Scope: ATMP scientific recommendation

Action: for adoption

4.2.2. Allogeneic neonatal human cardiac progenitor cells – H0005357

Intended for the treatment of cardiac failure

Scope: ATMP scientific recommendation

Action: for adoption

4.2.3. Allogeneic human enucleated red cell therapy expressing Anabaena variabilis (Av) phenylalanine ammonia lyase (AvPAL) – H0005355

Intended for the treatment of phenylketonuria (PKU)

Scope: ATMP scientific recommendation

Action: for adoption

4.3. Day 60 revised scientific recommendation (following list of questions)

No items

4.4. Finalisation of procedure

4.4.1. Autologous adipose tissue/micronised adipose tissue - H0005338/0001

Intended for autologous skin wound healing

Scope: comments received by the European Commission. Revised ATMP scientific recommendation

Action: for adoption

4.4.2. Allogeneic haematopoietic stem and progenitor cells treated ex vivo with the protein transduction domain of the human immunodeficiency virus-1 (HIV-1) transactivation protein fused to MYC transcription factor - H0005340/0001

Intended for the treatment of acute myelogenous leukaemia (AML)

Scope: the European Commission has raised no comments. Final ATMP scientific recommendation

Action: for information

4.4.3. Allogeneic haematopoietic stem and progenitor cells treated ex vivo with the protein transduction domain of the human immunodeficiency virus-1 (HIV-1) transactivation protein fused to MYC transcription factor - H0005341/0001

Intended for the treatment of myelofibrosis (MF)

Scope: the European Commission has raised no comments. Final ATMP scientific recommendation

Action: for information

4.4.4. Autologous dendritic cell, electroporated with messenger ribonucleic acid (mRNA) encoding tumour antigen Wilms tumour r (WT)-1 – H0005240

Intended for the treatment of lung cancer

Scope: ATMP scientific recommendation

Action: for adoption

4.5. Follow-up and guidance

No items

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

- 5.1. New requests – appointment of CAT Rapporteurs
- 5.2. CAT reports
- 5.3. List of Issues
- 5.4. Finalisation of SA procedures

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

- 6.1. Paediatric investigation plans
- 6.2. ITF briefing meetings in the field of ATMPs
- 6.3. Priority Medicines (PRIME) – Eligibility requests
 - 6.3.1. Month 0 - Start of the procedure
 - 6.3.2. Month 1 – Discussion of eligibility
 - 6.3.3. Month 2 – Recommendation of eligibility
 - 6.3.4. Ongoing support
 - No items

7. Organisational, regulatory and methodological matters

- 7.1. Mandate and organisation of the CAT
 - 7.1.1. Strategic Review & Learning meeting – joint CAT/Clinical trial facilitation group (CTFG), Bucharest, Romania, 13-14 June 2019

CAT resources: Simona Badoi

Scope: final agenda (version 9)

Action: for adoption

Note: a half day of this SRLM will be held jointly with the CTFG.

7.1.2. Strategic Review & Learning meeting – joint CAT/COMP/PDCO, Helsinki, Finland, 20-21 November 2019

CAT resources: Heli Suila
Scope: initial announcement
Action: for information

7.2. Coordination with EMA Scientific Committees

7.2.1. Committee for Medicinal Products for Human Use (CHMP)

Scope: Summary of Outcomes (SoO) for the April 2019 meeting
Action: for information

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. Healthcare Professionals Working Party (HCPWP) and Patients and Consumers Working Party (PCWP) - Nomination of CAT representative(s)

Scope: invitation to nominate CAT representatives to these working parties for the period covering June 2019 to May 2022.
Action: for nomination

7.4. Cooperation within the EU regulatory network

7.4.1. Notice to applicants

Scope: revised version of the text for the Notice to Applicants on the possibility to use literature data alone in support of a MA for ATMPs.
Action: for information
Note: bibliographic applications for ATMPs will be discussed at the next meeting of the Notice to Applicants to take place on 17 May 2019.

7.4.2. European Commission - draft guidelines on good clinical practice for advanced therapy medicinal products

Scope: adoption of GCP for ATMP Guidelines - consultation to CAT
Action: for discussion
Note: Article 4 of the ATMP Regulation mandates the Commission to draft GCP guidelines specific to ATMPs.

7.4.3. European Commission's Research and Innovation (R&I) Framework Programme

Scope: presentation on the future of the R&I programme in relation to ATMPs
Action: for information

7.5. Cooperation with international regulators

7.5.1. ATMP cluster teleconference with FDA, Health Canada and PMDA

The teleconference will take place

CAT: Martina Schübler-Lenz

Scope: draft agenda

Action: for discussion

7.5.2. International pharmaceutical regulators programme (IPRP) – cell therapy and gene therapy working groups

Scope: appointment of EU participants to cell therapy and gene therapy working group

Action: For information

7.5.3. Revision of Annex 2 of Pharmaceutical Inspection Co-operation Scheme (PIC/S) Good Manufacture Practice Guide

Scope: Revision of the Annex 2 to the PIC/S GMP guide

Action: for information

7.6. CAT work plan

None

7.7. Planning and reporting

None

7.8. Others

None

8. Any other business

8.1. BREXIT: extension of the period under 'Article 50'

Action: for information

Date of next CAT meeting:

19-21/06/2019

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations / Acronyms

AAV: Adeno-Associated Virus

AR: Assessment Report

ATMP: Advanced Therapy Medicinal Product

BWP: Biologics Working Party

CAT: Committee for Advanced Therapies

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

CTFG: Clinical Trial Facilitation Group

DG: Drafting Group

EC: European Commission

ERA: Environmental Risk Assessment

FDA: Food and Drug Administration

FL: Final Letter

GCG: Guideline Consistency Group

GCP: Good Clinical Practice

GLP: Good Laboratory Practice

GMO: Genetically-modified organism

GMP: Good Manufacturing Practice

GTMP: Gene Therapy Medicinal Product

HTA: Health Technology Assessment Bodies

HSPC: Hematopoietic Stem and Progenitor Cells

ITF: Innovative Task Force

JR: Joint Report

LoOI: List of outstanding issues

LoQ: List of questions

MA: Marketing Authorisation

MAA: Marketing Authorisation Application

MAH: Marketing Authorisation Holder

MSC: Mesenchymal stem cells

PDCO: Paediatric Committee

PMDA: Pharmaceuticals and Medical Devices Agency (Japan)

PIP: Paediatric Investigation Plan

PL: Package leaflet

PRAC: Pharmacovigilance and Risk Assessment Committee #

PRIME: Priority Medicines

RMP: Risk Management Plan
 RP: Reflection paper
 RSI: Request for supplementary information
 SAs: Scientific Advices
 SAG-O: Scientific Advisory Group Oncology
 SAWP: Scientific Advice Working Party
 TEP: Tissue Engineering Product
 SR: Summary Report
 SWP: Scientific Working Party
 SME: Small and medium size enterprises
 SmPC: Summary of Products Characteristics
 TT: Timetable


Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (section 2.9) and Post-authorisation activities (section 2.10).

New applications (sections 2.1. to 2.12.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found [here](#).

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.3) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures**). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue

for which the CAT would like to discuss with company representatives in person.

Re-examination procedures (new applications) under article 9(2) of regulation no 1234/2004 (section 2.6.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Withdrawal of applications (section 2.7.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

New applications (section 2.9.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

GMP and GCP Inspections Issues (section 2.10.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.12.)

This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, re-examination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, quality defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found [here](#).

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found [here](#).

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found [here](#).

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found [here](#).

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/